1. Home
  2. ELVR vs DBVT Comparison

ELVR vs DBVT Comparison

Compare ELVR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVR
  • DBVT
  • Stock Information
  • Founded
  • ELVR N/A
  • DBVT 2002
  • Country
  • ELVR Australia
  • DBVT France
  • Employees
  • ELVR N/A
  • DBVT N/A
  • Industry
  • ELVR Mining & Quarrying of Nonmetallic Minerals (No Fuels)
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ELVR Industrials
  • DBVT Health Care
  • Exchange
  • ELVR Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • ELVR 254.1M
  • DBVT 260.5M
  • IPO Year
  • ELVR N/A
  • DBVT N/A
  • Fundamental
  • Price
  • ELVR N/A
  • DBVT $9.90
  • Analyst Decision
  • ELVR
  • DBVT Buy
  • Analyst Count
  • ELVR 0
  • DBVT 4
  • Target Price
  • ELVR N/A
  • DBVT $14.81
  • AVG Volume (30 Days)
  • ELVR N/A
  • DBVT 36.4K
  • Earning Date
  • ELVR N/A
  • DBVT 11-05-2025
  • Dividend Yield
  • ELVR N/A
  • DBVT N/A
  • EPS Growth
  • ELVR N/A
  • DBVT N/A
  • EPS
  • ELVR N/A
  • DBVT N/A
  • Revenue
  • ELVR N/A
  • DBVT $3,800,000.00
  • Revenue This Year
  • ELVR N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • ELVR N/A
  • DBVT $1,045.66
  • P/E Ratio
  • ELVR N/A
  • DBVT N/A
  • Revenue Growth
  • ELVR N/A
  • DBVT N/A
  • 52 Week Low
  • ELVR N/A
  • DBVT $2.21
  • 52 Week High
  • ELVR N/A
  • DBVT $12.78
  • Technical
  • Relative Strength Index (RSI)
  • ELVR N/A
  • DBVT 55.65
  • Support Level
  • ELVR N/A
  • DBVT $9.58
  • Resistance Level
  • ELVR N/A
  • DBVT $10.19
  • Average True Range (ATR)
  • ELVR 0.00
  • DBVT 0.53
  • MACD
  • ELVR 0.00
  • DBVT 0.07
  • Stochastic Oscillator
  • ELVR 0.00
  • DBVT 66.39

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: